Search Results - "TASKINEN, M. R"

Diabetic dyslipidaemia: from basic research to clinical practice by TASKINEN, M.-R

“…The recognition that the increase of plasma triglyceride rich lipoproteins (TRLs) is associated with multiple alterations of other lipoproteins species that…”
Get full text

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study by Taskinen, M.-R, Rosenstock, J, Tamminen, I, Kubiak, R, Patel, S, Dugi, K.A, Woerle, H.-J

“…Aim: To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin administered as add-on therapy to…”
Get full text

Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes by Jansson Sigfrids, F., Dahlström, E. H., Forsblom, C., Sandholm, N., Harjutsalo, V., Taskinen, M.‐R., Groop, P.‐H.

“…Background We aimed to assess whether remnant cholesterol concentration and variability predict the progression of diabetic nephropathy (DN) and severe…”
Get full text

Ectopic lipid storage and insulin resistance: a harmful relationship by Borén, J., Taskinen, M.‐R., Olofsson, S.‐O., Levin, M.

“…Obesity increases the risk of metabolic diseases, including insulin resistance and type 2 diabetes, as well as cardiovascular disease. In addition to lipid…”
Get full text

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics by Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Sihlbom, C., Thorsell, A., Zhou, H., Taskinen, M.‐R., Borén, J.

“…Background Triglyceride‐rich lipoproteins and their remnants have emerged as major risk factors for cardiovascular disease. New experimental approaches are…”
Get full text

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes by MATIKAINEN, N, MÄNTTÄRI, S, SCHWEIZER, A, ULVESTAD, A, MILLS, D, DUNNING, B. E, FOLEY, J. E, TASKINEN, M.-R

“…We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein metabolism in patients with type 2…”
Get full text

Apolipoprotein B48 metabolism in chylomicrons and very low‐density lipoproteins and its role in triglyceride transport in normo‐ and hypertriglyceridemic human subjects by Björnson, E., Packard, C.J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., Sihlbom, C., Thorsell, A., Zhou, H., Taskinen, M.‐R., Borén, J.

“…Background Renewed interest in triglyceride‐rich lipoproteins as causative agents in cardiovascular disease mandates further exploration of the integrated…”
Get full text

Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study by Almgren, P., Lehtovirta, M., Isomaa, B., Sarelin, L., Taskinen, M. R., Lyssenko, V., Tuomi, T., Groop, L.

“…Aims/hypothesis To study the heritability and familiality of type 2 diabetes and related quantitative traits in families from the Botnia Study in Finland…”
Get full text

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study by Eliasson, B., Möller-Goede, D., Eeg-Olofsson, K., Wilson, C., Cederholm, J., Fleck, P., Diamant, M., Taskinen, M.-R., Smith, U.

“…Aims/hypothesis Pharmacological augmentation of glucagon-like peptide 1 receptor signalling by dipeptidyl peptidase 4 (DPP-4) inhibition reduced intestinal…”
Get full text

Overproduction of large VLDL particles is driven by increased liver fat content in man by Adiels, M, Taskinen, M.-R, Packard, C, Caslake, M. J, Soro-Paavonen, A, Westerbacka, J, Vehkavaara, S, Häkkinen, A, Olofsson, S.-O, Yki-Järvinen, H, Borén, J

“…Aims/hypothesis We determined whether hepatic fat content and plasma adiponectin concentration regulate VLDL₁ production. Methods A multicompartment model was…”
Get full text

Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations by Kotronen, A, Velagapudi, V. R, Yetukuri, L, Westerbacka, J, Bergholm, R, Ekroos, K, Makkonen, J, Taskinen, M.-R, Orešič, M, Yki-Järvinen, H

“…Aims/hypothesis The weak relationship between insulin resistance and total serum triacylglycerols (TGs) could be in part due to heterogeneity of TG molecules…”
Get full text

Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity by Taskinen, M.‐R., Söderlund, S., Bogl, L. H., Hakkarainen, A., Matikainen, N., Pietiläinen, K. H., Räsänen, S., Lundbom, N., Björnson, E., Eliasson, B., Mancina, R. M., Romeo, S., Alméras, N., Pepa, G. D., Vetrani, C., Prinster, A., Annuzzi, G., Rivellese, A., Després, J.‐P., Borén, J.

“…Background Overconsumption of dietary sugars, fructose in particular, is linked to cardiovascular risk factors such as type 2 diabetes, obesity, dyslipidemia…”
Get full text

Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate – Authors’ response by Björnson, E., Packard, C.J., Taskinen, M.‐R., Borén, J.

“…Click here to view the Letter to the Editor by Stellaard and Lütjohann…”
Get full text

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes by Matikainen, N., Taskinen, M.-R.

Get full text

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes by Bunck, M.C, Eliasson, B, Cornér, A, Heine, R.J, Shaginian, R.M, Taskinen, M.-R, Yki-Järvinen, H, Smith, U, Diamant, M

“…Preclinical studies suggest that incretin-based therapies may be beneficial for the bone; however, clinical data are largely lacking. We assessed whether the…”
Get full text

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial by Keech, AC, Prof, Mitchell, P, Prof, Summanen, PA, FEBO, O'Day, J, FRANZCO, Davis, TME, Prof, Moffitt, MS, DipTc, Taskinen, M-R, Prof, Simes, RJ, Prof, Tse, D, PhD, Williamson, E, PhD, Merrifield, A, PhD, Laatikainen, LT, Prof, d'Emden, MC, FRACP, Crimet, DC, MD, O'Connell, RL, MMedStat, Colman, PG, Prof

“…Summary Background Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to…”
Get full text

Intestinal alkaline phosphatase at the crossroad of intestinal health and disease – a putative role in type 1 diabetes by Lassenius, M. I., Fogarty, C. L., Blaut, M., Haimila, K., Riittinen, L., Paju, A., Kirveskari, J., Järvelä, J., Ahola, A. J., Gordin, D., Härma, M.‐A., Kumar, A., Hamarneh, S. R., Hodin, R. A., Sorsa, T., Tervahartiala, T., Hörkkö, S., Pussinen, P. J., Forsblom, C., Jauhiainen, M., Taskinen, M.‐R., Groop, P.‐H., Lehto, M.

“…Background Patients with type 1 diabetes have shown an increase in circulating cytokines, altered lipoprotein metabolism and signs of vascular dysfunction in…”
Get full text

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment by Groop, P.-H., Del Prato, S., Taskinen, M.-R., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., Woerle, H.-J.

“…Aims Renal disease is a frequent comorbidity of type 2 diabetes mellitus (T2DM) and an important factor complicating the choice of glucose‐lowering drugs. The…”
Get full text

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes by Taskinen, M.-R, Barter, P. J, Ehnholm, C, Sullivan, D. R, Mann, K, Simes, J, Best, J. D, Hamwood, S, Keech, A. C

“…Aims/hypothesis The apolipoprotein B (ApoB):apolipoprotein A (ApoA)-I ratio may be a better indicator of cardiovascular disease (CVD) risk in people with type…”
Get full text

Deep subcutaneous adipose tissue is more saturated than superficial subcutaneous adipose tissue by Lundbom, J, Hakkarainen, A, Lundbom, N, Taskinen, M-R

“…Upper body abdominal subcutaneous adipose tissue (SAT) can be divided into deep SAT (DSAT) and superficial SAT (SSAT) depots. Studies on adipose tissue fatty…”
Get full text